Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonardo Lopiano

Showing results (1-10 of 238) with videos related to

Pageof 24
Sort By:
Expert Review of Proteomics|May 10, 2008
Alpha-synuclein and Parkinson's disease: a proteomic viewMauro Fasano, Leonardo Lopiano
Frontiers in Neurology|May 1, 2023
Should we offer deep brain stimulation to Parkinson's disease patients with GBA mutations?Carlo Alberto Artusi, Leonardo Lopiano
Journal of Neurochemistry|January 19, 2006
Modifications of the iron-neuromelanin system in Parkinson's diseaseMauro Fasano, Bruno Bergamasco, Leonardo Lopiano
Biomarkers in Medicine|May 19, 2010
Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegenerationMauro Fasano, Tiziana Alberio, Leonardo Lopiano
The FEBS Journal|February 9, 2012
Cellular models to investigate biochemical pathways in Parkinson's diseaseTiziana Alberio, Leonardo Lopiano, Mauro Fasano
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 29, 2014
Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysisCarlo Lazzaro, Leonardo Lopiano, Dario Cocito
Proteomics. Clinical Applications|December 8, 2010
The proteomic approach in Parkinson's diseaseMauro Fasano, Bruno Bergamasco, Leonardo Lopiano
Journal of Clinical Medicine|December 9, 2020
Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PDCarlo Alberto Artusi, Leonardo Lopiano, Francesca Morgante
The Lancet. Neurology|October 19, 2004
Overt versus covert treatment for pain, anxiety, and Parkinson's diseaseLuana Colloca, Leonardo Lopiano, Michele Lanotte, et al.
Drug Design, Development and Therapy|June 18, 2021
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's DiseaseGiovanni Abbruzzese, Paolo Barone, Leonardo Lopiano, et al.
Pageof 24

Showing results (1-10 of 238) with videos related to

Sort By:
Pageof 24
Expert Review of Proteomics|May 10, 2008
Alpha-synuclein and Parkinson's disease: a proteomic viewMauro Fasano, Leonardo Lopiano
Frontiers in Neurology|May 1, 2023
Should we offer deep brain stimulation to Parkinson's disease patients with GBA mutations?Carlo Alberto Artusi, Leonardo Lopiano
Journal of Neurochemistry|January 19, 2006
Modifications of the iron-neuromelanin system in Parkinson's diseaseMauro Fasano, Bruno Bergamasco, Leonardo Lopiano
Biomarkers in Medicine|May 19, 2010
Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegenerationMauro Fasano, Tiziana Alberio, Leonardo Lopiano
The FEBS Journal|February 9, 2012
Cellular models to investigate biochemical pathways in Parkinson's diseaseTiziana Alberio, Leonardo Lopiano, Mauro Fasano
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 29, 2014
Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysisCarlo Lazzaro, Leonardo Lopiano, Dario Cocito
Proteomics. Clinical Applications|December 8, 2010
The proteomic approach in Parkinson's diseaseMauro Fasano, Bruno Bergamasco, Leonardo Lopiano
Journal of Clinical Medicine|December 9, 2020
Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PDCarlo Alberto Artusi, Leonardo Lopiano, Francesca Morgante
The Lancet. Neurology|October 19, 2004
Overt versus covert treatment for pain, anxiety, and Parkinson's diseaseLuana Colloca, Leonardo Lopiano, Michele Lanotte, et al.
Drug Design, Development and Therapy|June 18, 2021
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's DiseaseGiovanni Abbruzzese, Paolo Barone, Leonardo Lopiano, et al.
Pageof 24